Clinical Trials on Ebola Sudan Virus Disease in United Kingdom

Total 8777 results

International AIDS Vaccine Initiative
Biomedical Advanced Research and Development Authority

Active, not recruiting

Evaluation of Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine in Adults With Good General Health

Ebola Sudan Virus Disease

United States
University of Oxford
National Institute of Allergy and Infectious Diseases (NIAID); Wellcome Trust

Completed

A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo

Ebola | Ebola Zaire

United Kingdom
University of Oxford

Completed

A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV

Ebola Virus Disease

United Kingdom
University of Oxford

Unknown

A Phase I Study to Assess Ebola Vaccines cAd3-EBO Z and MVA-EBO Z

Ebola Virus Disease

United Kingdom
University of Oxford
University of Glasgow

Completed

Persistence of the Immune Response After Immunisation With Ebola Virus Vaccines (PRISM)

Ebola Virus Disease

United Kingdom
University of Oxford

Completed

A Study of a New Vaccine Against Two Types of Ebola

Ebola

United Kingdom
Janssen Vaccines & Prevention B.V.
Institut National de la Santé Et de la Recherche Médicale, France; University...

Completed

A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults

Ebola Viral Disease

France, United Kingdom
BioCryst Pharmaceuticals
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430

Ebola Virus Infection | Filovirus Infections

United Kingdom
National Institute of Allergy and Infectious Diseases...

Completed

Experimental Vaccine for Prevention of Ebola Virus Infection

Ebola Virus Disease | Ebola Hemorrhagic Fever | Ebola Virus Vaccines | Envelope Glycoprotein, Ebola Virus | Filovirus

United States
Cerus Corporation

Terminated

A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease

Acute Ebola Virus Disease

United States
National Institute of Allergy and Infectious Diseases...

Completed

Investigational Therapeutics for the Treatment of People With Ebola Virus Disease

Ebola Virus

United States, Congo, The Democratic Republic of the
National Institute of Allergy and Infectious Diseases...

Completed

Ebola and Marburg Virus Vaccines

Ebola Virus Disease | Ebola Vaccines | Marburg Virus Disease | Marburgvirus | Ebolavirus

United States
National Institute of Allergy and Infectious Diseases...

Completed

Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up

Ebola Virus Disease

United States, Liberia
Auro Vaccines LLC
United States Department of Defense; Accelovance

Completed

Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults

Ebola Virus Disease

United States
Arbutus Biopharma Corporation
United States Department of Defense

Terminated

Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802

Ebola Virus Infection

United States
Arbutus Biopharma Corporation
United States Department of Defense

Terminated

Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion

Ebola Virus Infection

United States
Emory University
Washington University School of Medicine; Merck Sharp & Dohme LLC

Not yet recruiting

Immunology of Ebola Vaccine

Ebola Virus Disease

United States
National Institute of Allergy and Infectious Diseases...

Suspended

Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein

Ebola Virus Disease

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z)

Ebola Disease | Immunisation

United States
Sarepta Therapeutics, Inc.
United States Department of Defense

Completed

Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus

Ebola Hemorrhagic Fever

United States
Sarepta Therapeutics, Inc.
United States Department of Defense

Withdrawn

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers

Ebola Hemorrhagic Fever

United States
National Institute of Allergy and Infectious Diseases...
Institut National de la Santé Et de la Recherche Médicale, France; The Ministry... and other collaborators

Completed

Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection

Ebola Virus Infection

United States, Guinea, Liberia, Sierra Leone
Janssen Vaccines & Prevention B.V.
Bavarian Nordic GmbH

Terminated

Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo

Hemorrhagic Fever, Ebola

France, United Kingdom, Kenya, United States, Uganda, Burkina Faso, Tanzania
National Institute of Allergy and Infectious Diseases...

Completed

A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers

Ebola Disease | Marburg Disease

United States
National Institute of Allergy and Infectious Diseases...

Completed

Experimental Ebola Vaccine Trial

Healthy | Hemorrhagic Fever, Ebola

United States
Albert B. Sabin Vaccine Institute
ICON plc; Oklahoma Blood Institute

Completed

Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults

Ebola Virus Disease | Marburg Virus Disease

United States
Janssen Vaccines & Prevention B.V.
Walter Reed Army Institute of Research (WRAIR)

Completed

Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo

Hemorrhagic Fever, Ebola

United States, Uganda, Kenya, Mozambique, Nigeria, Tanzania
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy Adults

Hemorrhagic Fever, Ebola

United States
Inovio Pharmaceuticals
GeneOne Life Science, Inc.; Defense Advanced Research Projects Agency

Completed

Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers

Ebola Vaccine

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants

Ebola

United States
Pfizer

Completed

A Study to Learn About the Effects of Multiple Doses of Sisunatovir on People With Respiratory Syncytial Virus (RSV) Infection

Respiratory Syncytial Virus Infections

United Kingdom
University of Edinburgh

Unknown

Hypertonic Saline Nasal Irrigation and Gargling in Suspected or Confirmed COVID-19 (ELVIS COVID-19)

Virus Diseases | COVID | Upper Respiratory Tract Infections | Virus | Virus Shedding

United Kingdom
Pfizer

Completed

Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV)

Respiratory Syncytial Virus (RSV)

United Kingdom
Janssen Sciences Ireland UC

Completed

Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection.

Respiratory Syncytial Virus Infections

United Kingdom
Enanta Pharmaceuticals, Inc
hVIVO Services Limited

Recruiting

A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model

RSV Infection

United Kingdom
Janssen Vaccines & Prevention B.V.

Completed

An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old Adults

Healthy

United Kingdom
Alios Biopharma Inc.

Completed

A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model

Respiratory Syncytial Virus Infections

United Kingdom
GlaxoSmithKline

Completed

A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults

Respiratory Synctial Virus Infections

United Kingdom
Imperial College London
Wellcome Trust

Completed

The Development of a Human Model of Respiratory Syncytial Virus Infection

Respiratory Syncytial Virus Infections | Respiratory Viral Infections

United Kingdom
Belfast Health and Social Care Trust
Queen's University, Belfast; Northern Ireland Clinical Trials Unit

Terminated

Epstein-Barr Virus Suppression in Chronic Obstructive Pulmonary Disease (EViSCO): a Phase 2 Randomised Control Trial (EViSCO)

COPD | EBV

United Kingdom
Arrow Therapeutics

Completed

A Study of the Safety and Efficacy of A-60444 in Adults With Respiratory Syncytial Virus (RSV) Infection Following HSCT

Respiratory Syncytial Virus Infections

United Kingdom
Respivert Ltd

Completed

RV568 - Viral Challenge With RSV

Respiratory Syncytial Virus Infections

United Kingdom
Imperial College London
European Commission

Withdrawn

Modelling the Interaction Between Synthetic Model Immunogens and the Induced B and T Cell Repertoires. (MOSAIC)

Virus Diseases

United Kingdom
Merck Sharp & Dohme LLC

Completed

Phase 2a Respiratory Syncytial Virus (RSV) Human Challenge Study of Clesrovimab (MK-1654) in Healthy Participants (MK-1654-005)

Respiratory Syncytial Viruses

United Kingdom
Pfizer

Completed

Pharmacokinetics and Safety of RV521 Formulations (C19007)

Respiratory Syncytial Virus Infections

United Kingdom
Pfizer

Completed

A Study to Learn About the Drug-drug Interactions of Sisunatovir in Healthy Adult Participants

Respiratory Syncytial Virus Infections

United Kingdom
Hvivo
Pfizer

Completed

Study of RSVpreF Vaccination and RSV Challenge in Healthy Adults

Respiratory Syncytial Virus Infections

United Kingdom
University of Oxford

Completed

RSV Observational Study 2

Respiratory Syncytial Virus Infections

United Kingdom
Alios Biopharma Inc.

Completed

A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176

Respiratory Syncytial Virus Infections

United Kingdom
Gilead Sciences

Completed

Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV) (Challenge)

Respiratory Syncytial Virus Infections

United Kingdom

Clinical Trials on Ebola Sudan Virus Disease in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations